Antineoplastics
1
Reactions 457 - 26 Jun 1993 Antineoplastics Myeloid leukaemia in children: incidence study In a US study of 3696 children treated for cancer, 4 children were found to have developed secondary acute myeloid leukaemia (AML). Two girls and 2 boys, aged 7-18 years, were initially treated for rhabdomyosarcoma (n = 1), non- Hodgkin’s lymphoma (2) and Hodgkin’s disease (1) with antineoplastic therapy including doxorubicin, cyclophosphamide, vincristine and prednisone. They had also received radiation therapy None of the children had been treated with etoposide and teniposide Secondary AML developed in these children 14-55 (median 38) months after the initial diagnosis. Two patients had 11q23 chromosomal abnormalities and 2 patients had 21q22 abnormalities. All patients initially achieved complete remission following antineoplastic therapy, but 3 relapsed and subsequently died. One patient remains disease-free following an allogenic bone marrow transplant. Author comment: These patients developed secondary AML following treatment with alkylating agents, relatively low doses of intercalating topoisomerase II inhibitors, and irradiation. ‘These treatment modalities, either alone or in combination, are carcinogenic and may cause secondary malignancies.’ Sandoval C, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. Journal of Clinical Oncology 11: 1039-1045, Jun 1993 - USA 800204289 1 Reactions 26 Jun 1993 No. 457 0114-9954/10/0457-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 457 - 26 Jun 1993
Antineoplastics
Myeloid leukaemia in children: incidence studyIn a US study of 3696 children treated for cancer, 4 children
were found to have developed secondary acute myeloidleukaemia (AML). Two girls and 2 boys, aged 7-18 years, wereinitially treated for rhabdomyosarcoma (n = 1), non-Hodgkin’s lymphoma (2) and Hodgkin’s disease (1) withantineoplastic therapy including doxorubicin,cyclophosphamide, vincristine and prednisone. They had alsoreceived radiation therapy None of the children had beentreated with etoposide and teniposide Secondary AMLdeveloped in these children 14-55 (median 38) months afterthe initial diagnosis. Two patients had 11q23 chromosomalabnormalities and 2 patients had 21q22 abnormalities. Allpatients initially achieved complete remission followingantineoplastic therapy, but 3 relapsed and subsequently died.One patient remains disease-free following an allogenic bonemarrow transplant.
Author comment: These patients developed secondary AMLfollowing treatment with alkylating agents, relatively low dosesof intercalating topoisomerase II inhibitors, and irradiation.‘These treatment modalities, either alone or in combination,are carcinogenic and may cause secondary malignancies.’Sandoval C, et al. Secondary acute myeloid leukemia in children previously treatedwith alkylating agents, intercalating topoisomerase II inhibitors, and irradiation.Journal of Clinical Oncology 11: 1039-1045, Jun 1993 - USA 800204289
1
Reactions 26 Jun 1993 No. 4570114-9954/10/0457-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
